Literature DB >> 28390900

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Xuetian Yue1, Yuhan Zhao1, Yang Xu2, Min Zheng3, Zhaohui Feng4, Wenwei Hu5.   

Abstract

Tumor suppressor p53 plays a central role in tumor suppression. p53 is the most frequently mutated gene in human cancer, and over half of human cancers contain p53 mutations. Majority of p53 mutations in cancer are missense mutations, leading to the expression of full-length mutant p53 (mutp53) protein. While the critical role of wild-type p53 in tumor suppression has been firmly established, mounting evidence has demonstrated that many tumor-associated mutp53 proteins not only lose the tumor-suppressive function of wild-type p53 but also gain new activities to promote tumorigenesis independently of wild-type p53, termed gain-of-function. Mutant p53 protein often accumulates to very high levels in tumors, contributing to malignant progression. Recently, mutp53 has become an attractive target for cancer therapy. Further understanding of the mechanisms underlying mutp53 protein accumulation and gain-of-function will accelerate the development of targeted therapies for human cancer harboring mutp53. In this review, we summarize the recent advances in the studies on mutp53 protein accumulation and gain-of-function and targeted therapies for mutp53 in human cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  gain-of-function; mutant p53; p53; protein stabilization; targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28390900      PMCID: PMC5663274          DOI: 10.1016/j.jmb.2017.03.030

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  128 in total

1.  Not all p53 gain-of-function mutants are created equal.

Authors:  S S Mello; L D Attardi
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

2.  Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Authors:  Fabio Valenti; Francesca Fausti; Francesca Biagioni; Tal Shay; Giulia Fontemaggi; Eytan Domany; Michael B Yaffe; Sabrina Strano; Giovanni Blandino; Silvia Di Agostino
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

4.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

5.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

6.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract.

Authors:  Mutsuo Furihata; Atsushi Kurabayashl; Manabu Matsumoto; Hiroshi Sonobe; Yuji Ohtsuki; Naotami Terao; Morimasa Kuwahara; Taro Shuin
Journal:  J Pathol       Date:  2002-05       Impact factor: 7.996

Review 9.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

10.  Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity.

Authors:  Antonio Garcia Trinidad; Patricia A J Muller; Jorge Cuellar; Marta Klejnot; Max Nobis; José María Valpuesta; Karen H Vousden
Journal:  Mol Cell       Date:  2013-06-06       Impact factor: 17.970

View more
  83 in total

1.  T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.

Authors:  Drew C Deniger; Anna Pasetto; Paul F Robbins; Jared J Gartner; Todd D Prickett; Biman C Paria; Parisa Malekzadeh; Li Jia; Rami Yossef; Michelle M Langhan; John R Wunderlich; David N Danforth; Robert P T Somerville; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2018-05-31       Impact factor: 12.531

2.  Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.

Authors:  Xuetian Yue; Fangnan Wu; Yanchen Li; Juan Liu; Michael Boateng; Kranthi Mandava; Cen Zhang; Zhaohui Feng; Jimin Gao; Wenwei Hu
Journal:  Cell Cycle       Date:  2020-04-10       Impact factor: 4.534

Review 3.  AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

Authors:  Bowen Yan; David Claxton; Suming Huang; Yi Qiu
Journal:  Exp Hematol       Date:  2020-06-20       Impact factor: 3.084

Review 4.  Patterns of mutations in TP53 mutated AML.

Authors:  John S Welch
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

5.  SIRT7-dependent deacetylation of NPM promotes p53 stabilization following UV-induced genotoxic stress.

Authors:  Alessandro Ianni; Poonam Kumari; Shahriar Tarighi; Nicolas G Simonet; Daniela Popescu; Stefan Guenther; Soraya Hölper; Andreas Schmidt; Christian Smolka; Shijing Yue; Marcus Krüger; Claudia Fiorillo; Alejandro Vaquero; Eva Bober; Thomas Braun
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

6.  TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Tomoaki Tanaka; Tetsuya Fujimura; Satoru Takahashi; Tomohiko Urano; Kazuhiro Ikeda; Satoshi Inoue
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

7.  Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.

Authors:  Nicholas W Fischer; Aaron Prodeus; Jean Gariépy
Journal:  JCI Insight       Date:  2018-08-09

Review 8.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

9.  Integrated analysis of miRNA and mRNA expression profiles in p53-edited PFF cells.

Authors:  Chuanmin Qiao; Weiwei Liu; Haoyun Jiang; Maozhang He; Qiang Yang; Yuyun Xing
Journal:  Cell Cycle       Date:  2020-03-26       Impact factor: 4.534

10.  Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.

Authors:  Ramona Schulz-Heddergott; Nadine Stark; Shelley J Edmunds; Jinyu Li; Lena-Christin Conradi; Hanibal Bohnenberger; Fatih Ceteci; Florian R Greten; Matthias Dobbelstein; Ute M Moll
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.